These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 22410974)
1. Regulation of stem cell-based therapies in Canada: current issues and concerns. von Tigerstrom B; Nguyen TM; Knoppers BM Stem Cell Rev Rep; 2012 Sep; 8(3):623-8. PubMed ID: 22410974 [TBL] [Abstract][Full Text] [Related]
2. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
3. The regulatory sciences for stem cell-based medicinal products. Yuan BZ; Wang J Front Med; 2014 Jun; 8(2):190-200. PubMed ID: 24733351 [TBL] [Abstract][Full Text] [Related]
5. American Society of Clinical Oncology policy statement: oversight of clinical research. American Society of Clinical Oncology J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281 [TBL] [Abstract][Full Text] [Related]
7. Regulation of Stem Cell-Based Research in India in Comparison with the US, EU and other Asian Countries: Current Issues and Future Perspectives. Jose J; George T; Thomas AM Curr Stem Cell Res Ther; 2020; 15(6):492-508. PubMed ID: 32250233 [TBL] [Abstract][Full Text] [Related]
8. The Future of Stem Cell Research and its Clinical Translation in Canada: Exploring Questions of Governance and Policy Options. Zarzeczny A Adv Exp Med Biol; 2020; 1247():1-16. PubMed ID: 31749135 [TBL] [Abstract][Full Text] [Related]
9. Risk management frameworks for human health and environmental risks. Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953 [TBL] [Abstract][Full Text] [Related]
10. Workshop to address gaps in regulation of minimally manipulated autologous cell therapies for homologous use in Canada. Chisholm J; von Tigerstrom B; Bedford P; Fradette J; Viswanathan S Cytotherapy; 2017 Dec; 19(12):1400-1411. PubMed ID: 28964743 [TBL] [Abstract][Full Text] [Related]
11. Peering from the shadows: stem cell research and the quest for regulation in Argentina. Harmon SH Stem Cell Rev Rep; 2012 Sep; 8(3):640-6. PubMed ID: 22076753 [No Abstract] [Full Text] [Related]
12. Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action. Caulfield T; Murdoch B BMC Med Ethics; 2019 Aug; 20(1):51. PubMed ID: 31383026 [TBL] [Abstract][Full Text] [Related]
13. The challenges of regulating stem cell-based products. von Tigerstrom BJ Trends Biotechnol; 2008 Dec; 26(12):653-8. PubMed ID: 18977047 [TBL] [Abstract][Full Text] [Related]
14. Fraudsters operate and officialdom turns a blind eye: a proposal for controlling stem cell therapy in China. Jiang L; Dong BH Med Health Care Philos; 2016 Sep; 19(3):403-10. PubMed ID: 26906907 [TBL] [Abstract][Full Text] [Related]
16. CellCAN: a unique enabler of regenerative medicine and cell therapy in Canada. Roy DC; Alarco AM; Isasi R Stem Cells Dev; 2014 Dec; 23 Suppl 1():24-8. PubMed ID: 25457957 [TBL] [Abstract][Full Text] [Related]
17. Legal and regulatory news from Europe. Hitchcock J Stem Cells Dev; 2014 Dec; 23 Suppl 1():44-6. PubMed ID: 25457961 [TBL] [Abstract][Full Text] [Related]
18. Research ethics across the 49th parallel: the potential value of pilot testing "equivalent protections" in Canadian research institutions. Lavery JV; McDonald M; Meslin EM Health Law Rev; 2005; 13(2-3):86-96. PubMed ID: 16459420 [TBL] [Abstract][Full Text] [Related]
19. Stem-cell battles. Stem-cell research in the USA is facing new legal and political challenges. Wolinsky H EMBO Rep; 2010 Dec; 11(12):921-4. PubMed ID: 21102641 [TBL] [Abstract][Full Text] [Related]
20. Sudden death for a challenge to federal funding of stem-cell research. Annas GJ N Engl J Med; 2011 Jun; 364(22):e47. PubMed ID: 21591936 [No Abstract] [Full Text] [Related] [Next] [New Search]